SPX LABS • RESEARCH LIBRARY
Semaglutide Clinical Trials: SUSTAIN, STEP and What the Studies Found
Semaglutide has been investigated in large Phase III programmes. This evidence-led guide explains the SUSTAIN and STEP trials, their populations, main findings and the limits of applying trial data beyond the studies.
Semaglutide clinical trials include large Phase III programmes that examined different clinical questions in different populations. The SUSTAIN studies primarily examined outcomes in type 2 diabetes, while the STEP programme investigated weight-management outcomes under controlled trial conditions.
The published record is substantial, but it is not a single result. Each programme used specific entry criteria, comparators, background care and endpoint definitions. A responsible reading keeps those details attached to the numbers rather than treating a headline figure as universally applicable.
This article is an educational review of published research. It is not medical advice, does not provide dosing or administration information, and does not describe any SPX Labs research material as a medicine. SPX Labs materials are for laboratory research only and are not for human or animal use.
Why Semaglutide Has a Large Phase III Evidence Base
Semaglutide progressed through several clinical-development programmes, each built around a specific question. The SUSTAIN programme included Phase III studies in type 2 diabetes, using controlled comparisons and predefined glycaemic endpoints. Later programmes examined other clinical questions with their own distinct protocols.
The STEP trials were randomised, double-blind studies designed around body-weight outcomes in adults who met the programmes’ inclusion criteria. Separately, SUSTAIN 6 examined cardiovascular outcomes in a high-risk type 2 diabetes population.
Together, these studies demonstrate why trial design matters. “Semaglutide research” is not one interchangeable body of evidence; it is a collection of programmes with different participants, aims and measurements.
SUSTAIN
Phase III and Phase IIIb diabetes-focused clinical research.
STEP
Large randomised trials with prespecified body-weight endpoints in selected adult populations.
SUSTAIN 6
A cardiovascular-outcomes trial in people with type 2 diabetes at high cardiovascular risk.
What “Phase III” Means in These Programmes
Phase III trials are generally larger confirmatory studies designed around a defined question. They use pre-specified primary outcomes, eligibility criteria and statistical plans so researchers can compare groups in a structured way.
That does not mean a Phase III result automatically applies to everyone. A study can be strong within its own population and still have limited relevance to people who were not enrolled, other formulations, different treatment settings or a separate research material.
When reading a Phase III paper, the first questions should be: who was studied, what was compared, how long did it last and what was the primary outcome?
| Programme | Participants | Main question | Example primary measure |
|---|---|---|---|
| SUSTAIN | Adults with type 2 diabetes in defined treatment settings | How did semaglutide compare with the protocol’s assigned comparator? | Change in HbA1c, a marker of average blood-glucose exposure |
| STEP 1 | Adults with obesity or overweight plus a weight-related condition, without diabetes | How did study-assigned semaglutide plus lifestyle intervention compare with placebo plus lifestyle intervention? | Percentage change in body weight at 68 weeks |
| SUSTAIN 6 | People with type 2 diabetes at high cardiovascular risk | Did major cardiovascular events differ from placebo? | First cardiovascular death, non-fatal heart attack or non-fatal stroke |
The SUSTAIN Programme: Diabetes-Focused Phase III Research
The SUSTAIN studies were designed to assess semaglutide in people with type 2 diabetes. Depending on the study, investigators compared it with placebo or an active comparator while participants also had defined background treatment.
A common primary measure was HbA1c. This is not a day-to-day finger-prick reading; it is a laboratory marker commonly used to estimate average glucose exposure over the preceding two to three months. Trials also reported other predefined outcomes, including body weight and safety measures.
In plain English, SUSTAIN asked whether the trial group assigned to semaglutide had different measured glucose-related outcomes from the group assigned to the comparator. It was not a general lifestyle or physique study.
SUSTAIN 6: Cardiovascular-Outcomes Research
SUSTAIN 6 was a randomised, double-blind, placebo-controlled cardiovascular-outcomes trial. It enrolled 3,297 people with type 2 diabetes who were at high cardiovascular risk and followed participants for approximately two years.
The primary outcome combined cardiovascular death, non-fatal heart attack and non-fatal stroke. Combined outcomes are used in event-driven trials because each component on its own may be less frequent, while the combined measure gives the study enough events for a robust comparison.
The publication reported that the primary outcome occurred in 6.6% of the semaglutide group and 8.9% of the placebo group. This result belongs specifically to the trial population, protocol and follow-up period.
3,297 participants
People with type 2 diabetes and high cardiovascular risk in the SUSTAIN 6 trial.
6.6% vs 8.9%
Published rates for the trial’s primary combined cardiovascular outcome.
How to read it
A group-level result in a defined high-risk study population, not an individual prediction.
STEP 1: What the 68-Week Trial Actually Found
STEP 1 was a double-blind, randomised, placebo-controlled study that enrolled 1,961 adults with obesity, or overweight plus at least one weight-related condition, who did not have diabetes. All participants received lifestyle intervention within the trial protocol.
At week 68, mean body-weight change was −14.9% in the semaglutide group and −2.4% in the placebo group. The estimated difference between groups was −12.4 percentage points. The study also reported that 86.4% of semaglutide participants and 31.5% of placebo participants reached at least 5% body-weight reduction.
In plain English: within this selected adult population and alongside the programme’s lifestyle support, the assigned semaglutide group had a substantially larger average reduction in body weight than the placebo group. This is a result of that formal trial; it is not a promise, a protocol or a forecast for an individual.
| STEP 1 result at 68 weeks | Semaglutide group | Placebo group | What it means |
|---|---|---|---|
| Mean change in body weight | −14.9% | −2.4% | Average group change under the trial protocol |
| Participants with at least 5% weight reduction | 86.4% | 31.5% | A prespecified threshold reported by the trial |
| Participants with at least 10% weight reduction | 69.1% | 12.0% | A group-level proportion, not an individual prediction |
| Discontinued because of gastrointestinal events | 4.5% | 0.8% | An adverse-event-related discontinuation result reported in the publication |
Why the Numbers Need Context
The STEP 1 result is often quoted without the details that make it interpretable. Participants were selected using study criteria, were followed for 68 weeks and received a structured lifestyle intervention alongside their randomised assignment. The reported average includes a distribution of individual responses rather than one guaranteed outcome.
The placebo group also changed over time, which is exactly why controlled trials matter. Comparing the two groups helps distinguish the trial-assignment effect from changes associated with the wider programme, participation and background lifestyle support.
The study also recorded adverse events and treatment discontinuations. Any evidence-led summary should include this information rather than reporting efficacy figures alone.
What the Research Did Not Establish
The trials did not test a generic “peptide” category, informal use or every population that might encounter online claims. They also did not verify the quality, identity, purity, stability, sterility or clinical equivalence of a separate research-material batch.
Results from SUSTAIN or STEP should not be used to create medical, treatment, dosing or product-performance claims for a laboratory research material. A published trial reports the study drug and protocol used by its investigators; a separate material requires its own analytical evidence and must not be presented as clinically interchangeable.
This distinction is especially important where clinical literature is discussed on a research-use-only website. Literature can be educational without being used as an implied product endorsement.
How to Read a Semaglutide Trial Responsibly
A useful reading framework prevents large clinical programmes from being reduced to social-media headlines.
- Check whether the study population had type 2 diabetes, obesity or another defined condition
- Identify the comparator and any background lifestyle or standard-care programme
- Read the primary endpoint before secondary outcomes or subgroup analyses
- Look at both the average change and the proportion of participants reaching a threshold
- Review the trial duration and what happened after treatment discontinuation, where reported
- Include safety reporting and treatment discontinuation rather than only efficacy figures
- Do not treat a study medicine as evidence about a separate research material
The Key Point to Remember
Semaglutide’s research record includes multiple Phase III programmes with clearly defined endpoints. SUSTAIN examined diabetes-focused outcomes and cardiovascular safety questions, while STEP 1 measured 68-week body-weight outcomes in a distinct adult population without diabetes.
The evidence is valuable because it provides controlled comparisons, participant numbers and exact published results. It remains evidence for the studied populations and protocols—not a substitute for clinical care, a dosing guide or proof that any separate research material is clinically equivalent.
For more evidence-led reading, visit the SPX Labs Research Library. For information about research-material documentation, see Quality & Testing and the COA Library.
Frequently Asked Questions
What are the SUSTAIN trials?
SUSTAIN is a programme of semaglutide clinical studies, including Phase III and Phase IIIb research in defined type 2 diabetes populations.
What was STEP 1?
STEP 1 was a 68-week, randomised, double-blind, placebo-controlled trial involving 1,961 adults with obesity or overweight plus a weight-related condition, without diabetes.
What did STEP 1 report?
The paper reported mean body-weight change of −14.9% in the semaglutide group and −2.4% in the placebo group at 68 weeks, within the trial protocol and study population.
What was SUSTAIN 6?
SUSTAIN 6 was a cardiovascular-outcomes trial in 3,297 people with type 2 diabetes at high cardiovascular risk. Its primary combined outcome occurred in 6.6% of the semaglutide group and 8.9% of the placebo group.
Do these clinical trials apply to all people or products?
No. The studies apply to their enrolled populations, study drug, comparators and protocols. They do not establish outcomes for unstudied populations or separate research materials.
Is this article medical advice?
No. This is an educational summary of published research and contains no dosing, administration or treatment guidance.
Scientific Sources
Research & Analytical Information Only
This article is provided for general laboratory and analytical education. SPX Labs research materials are supplied strictly for legitimate laboratory research, analytical testing and scientific evaluation and are not supplied for human or veterinary consumption or administration.
SPX Labs — Precision Research. Verified Quality.
